Prosecution Insights
Last updated: November 11, 2026
Application No. 18/178,253

CURABLE SILICONE COMPOSITION

Non-Final OA §103
Filed
Mar 03, 2023
Priority
Mar 10, 2022 — JP 2022-037543
Examiner
ZIMMER, MARC S
Art Unit
1765
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Dupont Toray Specialty Materials Kabushiki Kaisha
OA Round
3 (Non-Final)
79%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
96%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
1255 granted / 1580 resolved
+14.4% vs TC avg
Strong +16% interview lift
Without
With
+16.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
43 currently pending
Career history
1638
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
40.0%
+0.0% vs TC avg
§102
25.8%
-14.2% vs TC avg
§112
24.4%
-15.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1580 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on July 20, 2026 has been entered. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-5 are rejected under 35 U.S.C. 103 as being unpatentable over Yamazaki et al., WO 2022/004464 for the reasons outlined previously. Rejection of claims 6-10 is justified for the reasons that follow. Claim 6 sets a new lower limit defining the mass contribution of component (D). By the Examiner’s calculation, prior art Embodiment 6 (the focus of the last Office communication) has an amount of the prior art organohydrogensiloxane, c1-2, correlated with claimed component (D) of 11.1%. While the Examiner acknowledges that that this figure is outside of the currently claimed range, it is submitted that it is sufficiently close in magnitude that a skilled practitioner of the prior art invention has a reasonable expectation that it will be in possession of approximately the same properties as an analogous composition differing only in that the amount of c1-2 is 13% by weight. “A prima facie case of obviousness exists where the claimed ranges and prior art ranges do not overlap but are close enough that one skilled in the art would have expected [the claimed product and a product disclosed in the prior art] to have the same properties.” Titanium Metals Corp. of America v. Banner, 778 F.2d 775, 227 USPQ 773 (Fed. Cir. 1985). It is further noted that the experimental data provided by the Specification is not designed to establish 13 mass% of (D) as critical to the practice of the instant invention. Indeed, how could it be when claim allows that the weight contribution of (D) is as low as 5%? Several of the comparative examples contain none of component (D) whatsoever and at least one other contains no (C). Only one comparative example comprises both of (C) and (D) and it deviates from the claimed invention by containing more of the latter than had been contemplated by the original disclosure. Claims 7-10 further limit claim 6 in the same manner as claims 2-5 limit claim 1. Response to Arguments Applicant’s assertion of patentability over Yamazaki hinges on the notion that the reference requires the presence of a non-reactive silicone resin whereas the claims now demand its absence. The Examiner, however, respectfully disagrees that component (A2) is non-reactive (a concept that is not-at-all developed within the Specification). Instead, what the reference says is that (A2) does not contain a curing reactive functional group in the form of a carbon-carbon double bond [0044]. What it does contain though is up to 5 mol% of silicon bound hydroxyl- or alkoxy groups. See [0045] and [0047]. It seems that Applicant may have intended that the non-reactive silicone resin [0058] representing one permutation of the organic filler of [0053] is one that won’t participate in the reaction by which the instant composition is cured. Because Applicant doesn’t address the meaning of “non-reactive”, it is appropriate for the Examiner to apply a broadest reasonable interpretation standard that assigns to “non-reactive silicone resin” the condition that it be entirely devoid of any groups that may participate in a reaction of some kind. Certainly, it can be said that the silicon-bound hydroxyl/alkoxy groups are reactive and thus prior art (A2) is, in contrast to what Applicant asserts, not a non-reactive silicone resin. U.S. Patent Application Publication No. 2007/0106016 is cited as being of interest but not especially germane to the patentability of the instant claims for, while Table 2 summarizes the makeup of compositions that contain all of claimed components (A) to (E), they are added in much different proportions. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARC S ZIMMER whose telephone number is (571)272-1096. The examiner can normally be reached M-F 8:30-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heidi Kelley can be reached at 571-270-1831. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. August 13, 2026 /MARC S ZIMMER/Primary Patent Examiner, Art Unit 1765
Read full office action

Prosecution Timeline

Mar 03, 2023
Application Filed
Oct 15, 2025
Non-Final Rejection mailed — §103
Jan 08, 2026
Response Filed
Feb 18, 2026
Final Rejection mailed — §103
Jul 20, 2026
Request for Continued Examination
Jul 22, 2026
Response after Non-Final Action
Aug 17, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780992
TEMPORARY HIGH-TEMPERATURE-RESISTANT DISPERSING AGENT AND PREPARATION AND USE METHOD THEREOF
3y 4m to grant Granted Nov 03, 2026
Patent 12781050
CURABLE ORGANOPOLYSILOXANE COMPOSITION AND SEMICONDUCTOR DEVICE
3y 0m to grant Granted Nov 03, 2026
Patent 12780985
POLYCARBONATE COPOLYMER
2y 10m to grant Granted Nov 03, 2026
Patent 12767857
CURABLE COMPOSITION, ARTICLE, CHECKING METHOD, AND ADHESIVE COMPOSITION
3y 5m to grant Granted Oct 20, 2026
Patent 12767821
CURABLE COMPOSITION, AND CURED PRODUCT
3y 3m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
79%
Grant Probability
96%
With Interview (+16.1%)
2y 5m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1580 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month